News | Antiplatelet and Anticoagulation Therapies | November 06, 2017

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents

Study finds patients may not benefit from recommended longer periods of DAPT

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents. Photo courtesy of Siemens Healthineers

Photo courtesy of Siemens Healthineers

November 6, 2017 —  The first trial to evaluate the safety of dual antiplatelet therapy (DAPT) for less than 12 months in ST-elevation myocardial infarction (STEMI) found six months of DAPT was non-inferior to 12 months among patients treated with second-generation drug-eluting stents (DES).

Findings were reported at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium sponsored by the Cardiovascular Research Foundation (CRF), Oct. 29-Nov. 2 in Denver.

International guidelines recommend 12 months of DAPT for STEMI patients after primary peructaneous coronary intervention (PCI) with DES due to ongoing atherothrombotic risk. While longer duration DAPT therapy reduces the risk of ischemic events, it is also associated with a higher risk of major bleeding that can sometimes be fatal. Second-generation DES have a lower stent thrombosis risk than their predecessors, questioning the need for an extended duration of DAPT.

DAPT STEMI was a prospective, randomized trial designed to evaluate whether six months of DAPT was non-inferior to 12 months in event-free patients at six-month follow-up after primary PCI. The study enrolled 1,100 STEMI patients who underwent primary PCI with a second-generation zotarolimus-eluting stent. Those who were event-free at six months and agreed to continue with the study (N=870) were randomized to single antiplatelet therapy (SAPT, N=433) or DAPT (N=437). Baseline and procedural characteristics were similar in both arms.

The study’s primary endpoint was a patient-oriented composite of all-cause mortality, any myocardial infarction, any revascularization, stroke or thrombolysis in myocardial infarction (TIMI) major bleeding at 18-month follow-up after randomization (i.e. two years after primary PCI). The primary endpoint occurred in 4.8 percent of the SAPT group versus 6.6 percent for the DAPT group {HR 0.73; 95% CI (0.41-1.27); P= 0.26; Pnon-inferiority=0.004}. The incidences of the individual components of the primary endpoint were as follows:

  • Mortality: 0.7 percent in SAPT vs. 1.4 percent in DAPT {HR 0.51; 95% CI (0.13-2.02); P=0.33};
  • Myocardial infarction: 1.8 percent vs. 1.8 percent {HR 1.02; 95% CI (0.38-2.71); P=0.97;
  • Revascularization: 3 percent vs. 3.9 percent {HR 0.87; 95% CI (0.42-1.83); P=0.72;
  • Stroke: 0.7 percent vs. 0.7 percent {HR 1.02; 95% CI (0.21-5.03); P=0.99; and
  • TIMI major bleeding: 0.2 percent vs. 0.5 percent {HR 0.51; 95% CI (0.05-5.57); P=0.58.

“For the first time in the modern DES era, this trial indicates that STEMI patients, similar to stable angina patients, may not benefit from prolonged DAPT therapy beyond six months as currently recommended,” said Elvin Kedhi, M.D., Ph.D., head of the Interventional Cardiology and Clinical Research and Innovation at Isala Hartcentrum in Zwolle, The Netherlands. “This sets the stage for further dedicated research on this important topic.”

The DAPT STEMI trial was funded by Maasstad Cardiovascular Research. Kedhi reported receiving consulting fees/honoraria or institutional grants from Medtronic, Abbott, Meril and OrbusNeich.

Watch a VIDEO interview on tthis study

For more information: www.tctconference.com

 

Related Content

TCT 2017 Late-breaking Clinical Trial Presentations

 

 

Related Content

Thrombolytic Science Initiates Phase 2 Trial of Novel Ischemic Stroke Treatment Regimen
News | Antiplatelet and Anticoagulation Therapies | September 07, 2018
A new Phase 2 clinical trial looks to confirm the efficacy and safety of Thrombolytic Science LLC’s (TSI) sequential...
Bleeds and Benefit With Aspirin Balanced in Diabetes Patients
News | Antiplatelet and Anticoagulation Therapies | September 05, 2018
Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease,...
Extended Post-Hospital Oral Anticoagulant Use Reduces Non-Fatal Blood Clots
News | Antiplatelet and Anticoagulation Therapies | August 31, 2018
Use of an oral anticoagulant in medically ill patients for 45 days following hospital discharge reduces the rate of non...
AFib Patients Want More Information About Anticoagulation Reversal
News | Antiplatelet and Anticoagulation Therapies | June 27, 2018
Results from a 902-person, five-country survey of people living with atrial fibrillation (AF) reinforce the importance...
Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018
News | Antiplatelet and Anticoagulation Therapies | May 18, 2018
May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated...
The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in...
The Xarelto booth at ACC.18

The Xarelto booth at the 2018 American College of Cardiology meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 14, 2018
March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiolo
Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients
News | Antiplatelet and Anticoagulation Therapies | February 19, 2018
A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International Stroke Conference (ISC...
Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018
Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet...
Overlay Init